• 1. Excitation energies from ground-state density-functionals by means of generator coordinates
  A. B. F. da Silva,K. Capelle Phys. Chem. Chem. Phys., 2009,11, 4564-4569
• 2. Dissolved oxygen sensor based on fluorescence quenching of oxygen-sensitive ruthenium complexes immobilized in sol–gel-derived porous silica coatings
  Analyst, 1996,121, 785-788
• 3. Evolution of shape, size, and areal density of a single plane of Si nanocrystals embedded in SiO2 matrix studied by atom probe tomography
  Bin Han,Yasuo Shimizu,Gabriele Seguini,Celia Castro,Gérard Ben Assayag,Koji Inoue,Yasuyoshi Nagai,Sylvie Schamm-Chardon,Michele Perego RSC Adv., 2016,6, 3617-3622
• 4. Fe3O4/PEG-SO3H as a heterogeneous and magnetically-recyclable nanocatalyst for the oxidation of sulfides to sulfones or sulfoxides
  Saeideh Mirfakhraei,Malak Hekmati,Fereshteh Hosseini Eshbala,Hojat Veisi New J. Chem., 2018,42, 1757-1761
• 5. Evolutionary de novo design of phenothiazine derivatives for dye-sensitized solar cells?
  Vishwesh Venkatraman,Marco Foscato,Vidar R. Jensen,Bj?rn K?re Alsberg J. Mater. Chem. A, 2015,3, 9851-9860

Guvacoline Hydrobromide: A Comprehensive Overview

Guvacoline Hydrobromide, also known by its CAS number 17210-51-4, is a compound that has garnered significant attention in the scientific and pharmaceutical communities. This compound is primarily recognized for its role in various pharmacological applications, particularly in the field of neuroscience. The name Guvacoline Hydrobromide itself suggests its chemical composition, with "hydrobromide" indicating the presence of a bromine atom in its structure.

Recent studies have highlighted the potential of Guvacoline Hydrobromide as a promising agent in the treatment of neurological disorders. Researchers have explored its ability to modulate neurotransmitter systems, particularly dopamine and serotonin pathways, which are crucial for regulating mood, cognition, and motor functions. This modulation has shown potential benefits in conditions such as depression, anxiety, and Parkinson's disease.

The chemical structure of CAS 17210-51-4 plays a pivotal role in its pharmacological activity. The compound's hydrobromide form ensures better solubility and bioavailability, making it more effective when administered therapeutically. Its molecular framework allows it to interact with specific receptors in the brain, thereby influencing neuronal communication.

In terms of synthesis, Guvacoline Hydrobromide is typically derived from complex organic reactions involving multiple steps. These reactions require precise control over temperature and pH levels to ensure optimal yield and purity. The synthesis process often involves the use of advanced chromatographic techniques to isolate the final product.

One of the most recent breakthroughs involving Guvacoline Hydrobromide is its application in drug delivery systems. Scientists have developed nanotechnology-based delivery mechanisms to enhance the compound's efficacy and reduce potential side effects. These innovations have opened new avenues for personalized medicine, where treatments can be tailored to individual patient needs.

The pharmacokinetics of CAS 17210-51-4 have also been extensively studied. Research indicates that the compound exhibits moderate absorption rates when administered orally, with peak plasma concentrations achieved within 2-3 hours. Its half-life is relatively short, necessitating frequent dosing schedules for sustained therapeutic effects.

Safety profile assessments have revealed that Guvacoline Hydrobromide is generally well-tolerated at therapeutic doses. However, potential side effects include dizziness, nausea, and mild gastrointestinal disturbances. Long-term studies are currently underway to evaluate the compound's safety profile over extended periods of use.

In conclusion, Guvacoline Hydrobromide (CAS 17210-51-4) represents a significant advancement in pharmacological research. Its unique chemical properties and therapeutic potential make it a valuable tool in addressing various neurological conditions. As research continues to unfold, this compound holds promise for revolutionizing treatment approaches in neuroscience.

• 63-75-2(arecoline)
• 18513-76-3(Ethyl 1,2,5,6-tetrahydropyridine-3-carboxylate)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)